Profile data is unavailable for this security.
About the company
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.
- Revenue in EUR (TTM)140.87m
- Net income in EUR28.41m
- Incorporated--
- Employees183.00
- LocationPharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
- Phone+31 715247400
- Fax+31 715247445
- Websitehttps://www.pharming.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basilea Pharmaceutica AG | 95.72m | -28.29m | 402.77m | 225.00 | -- | -- | -- | 4.21 | -2.89 | -2.89 | 9.79 | -6.21 | 0.3353 | 1.37 | 24.36 | 471,520.00 | -9.91 | -12.62 | -12.88 | -16.04 | 80.87 | -- | -29.55 | -57.63 | 3.90 | -3.69 | 1.51 | -- | 17.00 | 20.97 | -61.94 | -- | -12.78 | -- |
| Cassiopea SpA | 0.00 | -12.65m | 403.28m | 8.00 | -- | 27.79 | -- | -- | -1.40 | -1.40 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -56.24 | -33.21 | -61.94 | -35.53 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.32 | -- | -- | -- |
| Pharma Mar SA | 137.36m | -25.30m | 405.22m | 599.00 | -- | 35.32 | -- | 2.95 | -0.1143 | -0.0664 | 0.6208 | 0.0515 | 0.781 | 1.43 | 5.61 | 229,320.50 | -14.40 | -4.94 | -24.65 | -7.98 | 80.83 | 76.90 | -18.43 | -5.60 | 1.31 | -4.41 | 0.9293 | -- | 2.33 | 2.77 | 42.59 | -- | -18.18 | -- |
| Selcuk Ecza Deposu Ticaret ve Sanayi AS | 2.23bn | 76.56m | 429.53m | 6.43k | 5.61 | 1.02 | 5.17 | 0.1926 | 0.7932 | 0.7932 | 23.10 | 4.38 | 2.16 | 8.95 | 10.05 | 2,213,597.00 | 7.40 | 5.97 | 18.96 | 13.55 | 8.23 | 7.50 | 3.43 | 2.77 | 1.11 | 14.34 | 0.0111 | 19.82 | 26.02 | 20.79 | 29.95 | 20.76 | 23.74 | 12.70 |
| Celon Pharma SA | 29.14m | 6.72m | 492.13m | 297.00 | 73.23 | 4.61 | 43.85 | 16.89 | 0.6364 | 0.6364 | 2.76 | 10.12 | 0.2213 | 1.91 | 4.51 | 418,076.90 | 5.10 | -- | 5.33 | -- | 65.27 | -- | 23.06 | -- | 6.95 | -- | 0.0033 | -- | 16.92 | -- | 15.93 | -- | -- | -- |
| BioArctic AB | 80.15m | 45.10m | 493.79m | 39.00 | 13.30 | 6.22 | 10.81 | 6.16 | 5.31 | 5.31 | 9.43 | 11.35 | 0.7218 | -- | -- | 27,228,550.00 | 40.61 | -- | 55.29 | -- | 96.08 | -- | 56.27 | -- | -- | -- | 0.0291 | -- | 407.42 | -- | 2,417.66 | -- | -- | -- |
| Pharming Group N.V. | 140.87m | 28.41m | 503.29m | 183.00 | 19.12 | 7.29 | 15.37 | 3.57 | 0.0424 | 0.0424 | 0.2061 | 0.1111 | 0.761 | 1.28 | 7.58 | 769,786.90 | 15.34 | -15.97 | 22.83 | -24.78 | 83.97 | 83.46 | 20.16 | -31.00 | 1.41 | 1.26 | 0.5085 | -- | 50.78 | 81.59 | 132.78 | -- | 160.02 | -- |
| Eckert & Ziegler AG | 176.52m | 19.60m | 550.47m | 803.00 | 27.26 | 4.13 | 18.55 | 3.12 | 3.81 | 3.81 | 34.44 | 25.16 | 0.7533 | 3.24 | 7.08 | 224,010.20 | 8.70 | 5.71 | 10.23 | 7.20 | 45.65 | 46.49 | 11.55 | 8.06 | 2.86 | 62.65 | 0.13 | 33.90 | 21.70 | 7.57 | 39.05 | 12.29 | -8.70 | 14.87 |
| Zentiva SA | 106.56m | 59.67m | 551.59m | 578.00 | 9.11 | 3.95 | 8.68 | 5.18 | 0.3995 | 0.3995 | 0.7133 | 0.9217 | 0.7062 | 2.23 | 3.12 | 872,232.00 | 39.55 | 22.47 | 51.74 | 29.91 | 55.38 | 54.86 | 56.00 | 24.69 | 2.77 | -- | 0.00 | 33.26 | 0.6606 | 9.71 | 192.96 | 45.33 | 11.11 | -- |
| Recipharm AB (publ) | 633.61m | 18.43m | 569.86m | 5.28k | 40.21 | 1.39 | 7.14 | 0.8994 | 2.84 | 2.84 | 97.31 | 82.34 | 0.5296 | 2.87 | 5.24 | 981,308.80 | 1.54 | 1.43 | 1.75 | 1.68 | 47.54 | 47.96 | 2.91 | 2.56 | 1.55 | 3.54 | 0.462 | 55.87 | 19.54 | 24.57 | 193.49 | 11.05 | 36.15 | -- |
| Oxford BioMedica plc | 74.24m | 8.38m | 590.60m | 377.00 | 63.28 | 13.17 | 44.65 | 7.96 | 0.1094 | 0.1094 | 0.9644 | 0.5256 | 0.7512 | 6.00 | 3.45 | 177,130.00 | 8.48 | -14.68 | 11.83 | -19.78 | 65.91 | 60.85 | 11.29 | -24.62 | 2.29 | 2.73 | 0.5422 | -- | 77.65 | 65.52 | 183.63 | -- | 61.04 | -- |
| Cellectis SA | 14.91m | -61.10m | 597.85m | 149.00 | -- | 1.72 | -- | 40.09 | -1.49 | -1.49 | 0.3585 | 8.19 | 0.0402 | -- | 5.40 | 100,096.20 | -18.97 | -18.99 | -23.23 | -25.03 | -- | 14.34 | -472.19 | -137.77 | 9.74 | -- | 0.0762 | -- | -36.43 | 24.66 | 20.81 | -- | 42.19 | -- |
Data as of Jul 16 2019. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR
12.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co.as of 31 May 2019 | 19.51m | 3.14% |
| Polar Capital LLPas of 25 Apr 2018 | 18.50m | 2.98% |
| FMR Co., Inc.as of 09 Apr 2018 | 13.56m | 2.18% |
| Goldman Sachs Asset Management LPas of 31 Oct 2018 | 10.70m | 1.72% |
| BlackRock Fund Advisorsas of 03 Jul 2019 | 7.14m | 1.15% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 5.53m | 0.89% |
| TIAA-CREF Investment Management LLCas of 31 May 2019 | 1.22m | 0.20% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2019 | 858.41k | 0.14% |
| Principal Global Investors LLCas of 31 Jan 2019 | 700.67k | 0.11% |
| SEI Investments Management Corp.as of 31 May 2019 | 609.14k | 0.10% |
More ▼
Data from 31 Dec 2018 - 31 Mar 2019Source: FactSet Research Systems Inc.
